Privately-held Immunocore Ltd of the UK has secured a licencing deal with Genentech (Roche) to discover and develop therapies against multiple of cancer targets. The deal is potentially valued at more than $320 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
